HC Wainwright Reaffirms 'Buy' Rating on Galectin Therapeutics with $6.00 Price Target

Galectin Therapeutics (GALT) has received a reaffirmed "Buy" rating from HC Wainwright & Co. with a price target of $6.00 USD, unchanged from previous evaluations. The company focuses on drug research for fibrotic disease, cancer, and other diseases. Analysts forecast an average target price of $6.00, implying a 62.60% upside from the current price of $3.69.

Galectin Therapeutics (GALT), a clinical-stage biopharmaceutical company, has received a reaffirmed "Buy" rating from HC Wainwright & Co. with a price target of $6.00 USD, unchanged from previous evaluations. The analyst, Matthew Keller, maintained the rating despite no changes in the price target. This consistent rating reflects the analyst's confidence in GALT's pipeline and the potential of its lead drug, belapectin (GR-MD-02), which is in development for fibrotic diseases, cancer, and other diseases [1].

Galectin Therapeutics focuses on drug research and development, with belapectin demonstrating preclinical efficacy in reversing liver fibrosis and cirrhosis. The company's recent financial results for the quarter ended June 30, 2025, showed a net loss of $7.6 million, down from $12.4 million in the same period last year. The company has $13.8 million in cash and cash equivalents, with an additional $10 million line of credit announced in early July, expected to fund operations through the second half of 2026 [2].

Analysts forecast an average target price of $6.00, implying a 62.60% upside from the current price of $3.69. The consensus brokerage recommendation is "Outperform," indicating a positive outlook on the company's prospects [1]. Galectin's lead development program is in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis, a significant area of unmet medical need.

The company's NAVIGATE trial, which assesses belapectin's efficacy in patients with MASH cirrhosis, has shown promising results. The trial's primary endpoint, the prevention of esophageal varices after 18 months of treatment, was met, with additional data supporting the drug's potential to modify disease progression in this high-risk population [2].

In conclusion, Galectin Therapeutics continues to hold a 'Buy' rating from HC Wainwright & Co., with a consistent price target of $6.00 USD. The company's pipeline and recent trial results indicate a positive outlook, supported by analyst forecasts and brokerage recommendations.

References:
[1] https://www.gurufocus.com/news/3062379/galectin-therapeutics-galt-rating-reaffirmed-by-hc-wainwright-co-galt-stock-news
[2] https://www.globenewswire.com/news-release/2025/08/14/3133433/27423/en/Galectin-Therapeutics-Reports-Financial-Results-for-the-Quarter-Ended-June-30-2025-and-Provides-Business-Update.html